Physician profile
Amer Khan
NPI 1609010883
$70,803.39
in general payments reported to CMS, 2019-2025
26 companies · $5,153 in 2025
The $5,153 reported for 2025 was more than what 93% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $2,214 · 2021: $7,212 · 2022: $11K · 2023: $23K · 2024: $22K · 2025: $5,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Food and Beverage: $6,910 · Travel and Lodging: $5,685 · Education: $92.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,150.00 |
| Food and Beverage | $6,910.30 |
| Travel and Lodging | $5,685.14 |
| Education | $92.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $59,670.59 | 2019-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $2,931.00 | 2019-2025 | Vafseo, Auryxia |
| Horizon Therapeutics Plc | $1,649.24 | 2021-2023 | Krystexxa |
| Vifor Pharma, INC. | $1,049.79 | 2019-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $874.42 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $696.07 | 2019-2025 | Krystexxa, Tavneos |
| Daiichi Sankyo INC. | $605.42 | 2019-2025 | Injectafer |
| Travere Therapeutics, INC. | $488.35 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $453.35 | 2020-2025 | Acthar |
| Opko Pharmaceuticals, LLC | $405.10 | 2020-2024 | Rayaldee |
| Calliditas Therapeutics US INC. | $317.44 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $271.49 | 2021-2025 | |
| Glaxosmithkline, LLC. | $232.76 | 2021-2024 | Benlysta, Jesduvroq |
| Ardelyx, INC. | $149.57 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $146.72 | 2023-2025 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $130.07 | 2024-2025 | |
| Novo Nordisk INC | $125.73 | 2019 | |
| Alexion Pharmaceuticals, INC. | $123.51 | 2022-2024 | Ultomiris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $118.32 | 2020-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $116.60 | 2021-2024 | Lupkynis |
| Takeda Pharmaceuticals U.S.A., INC. | $84.10 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $77.73 | 2022-2025 | Givlaari |
| Medtronic, INC. | $34.84 | 2023 | Ellipsys Vascular Access System |
| Shield Therapeutics INC | $22.69 | 2023 | Accrufer |
| Strongbridge US INC. | $17.00 | 2019 | |
| Genzyme Corporation | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.